Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Fig. 3

Swimmer plots depicting patients’ responses to lenalidomide (A) or ibrutinib (B), in combination with R-MPV, over time. Lenalidomide dose K: 20 mg per day D1 to 14; Lenalidomide dose K-1: 15 mg per day D1 to 21; Ibrutinib dose K: 420 mg per day (D3 to 14 and D17 to 28); Ibrutinib dose K + 1: 560 mg per day (D3 to 14 and D17 to 28); CR: complete response; uCR: unconfirmed complete response; PR: partial response; SD: stable disease; PD: progressive disease; DLT: dose-limiting toxicity

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us